Strimvelis, (autologous CD34+ cells transduced to express ADA) the first ex vivo stem cell gene therapy has been approved to treat patients with ADA-SCID (severe combined immunodeficiency due to adenosine deaminase deficiency). Children born with ADA-SCID do not have a heathy, fully functioning immune system and are unable to successfully combat everyday infections.
www.gsk.com › en-gb › Media › Press releases
We’d like to give a very warm welcome to our latest IGNITE cohort. Having begun on 31st October with an introductory session, we hope our latest IGNITEES find the programme insightful and enjoyable!
read more >>
In recognition of both Health Literacy Month and Breast Cancer Awareness Month, we’re looking at the unmet treatment education needs of people living with breast cancer who experience low health literacy.
Our team will be at the Working in and around #MedComms careers event on Thursday 10 November at the Radisson Hotel & Conference Centre, London Heathrow.
Whether you’re new to healthcare communications or looking to further progress your career, we’d love to see you there.
read more >>